PATENT CLAIMS

- 1. Use of melatonin and/or of a chemically modified derivative thereof for making pharmaceutical preparations for the regulation of insulin release by influencing the β -cell of the pancreatic islets through a melatonin-specific receptor.
- 2. Use of melatonin and/or of a chemically modified derivative thereof according to Claim 1, characterized in that the regulating action consists of inhibiting insulin release.
- 3. Use according to Claim 1 for treating hyperinsulinemia.
- 4. Use according to at least one of Claims 1 to 3, characterized in that the pharmaceutical preparation is made in the form of tablets, capsules, coated tablets, transdermal therapy systems, ampules, suppositories, gels, ointments, implants or buccally administered systems.